Buspirone Hcl
Brand names: Buspirone Hcl
At a glance
- Medicare prescriptions, 2024
- 7,088,299
- Medicare drug cost
- $100.3M
- Average cost per prescription
- $14.15
- Clinicians who prescribed it
- 147,254
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Buspirone hydrochloride tablets, USP are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets, USP has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets, USP relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder is described in the American Psychiatric Association's Diagnostic and Statistical Manual, III1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth,…
From the FDA-approved prescribing information (label dated June 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 23.7%
- Nurse Practitioners 19.4%
- Internal Medicine 16.8%
- Psychiatry 13.9%
- Psychiatric Nurse Practitioners 13.9%
- Physician Assistants 5.8%
- Geriatric Medicine 1.6%
- General Practice 1.3%
- Neurology 0.7%
- Child & Adolescent Psychiatry 0.6%
- Hospitalist 0.4%
- Physical Medicine & Rehabilitation (PM&R) 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 55% from 2019 to 2024.
Biggest change by state since 2019
- Puerto Rico +92%
- Indiana +86%
- Louisiana +69%
- Alabama +68%
- South Carolina +67%
- Maine (smallest change) +35%
- Wyoming (smallest change) +36%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Advagen Pharma Ltd
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg | white oval tablet, 8 mm, scored to split in 2 | UPARROWHEAD 79 |
| 7.5 mg | white oval tablet, 9 mm, scored to split in 2 | UPARROWHEAD 90 |
| 10 mg | white oval tablet, 10 mm, scored to split in 2 | UPARROWHEAD 91 |
| 15 mg | white rectangle tablet, 15 mm, scored to split in 3 | UPARROWHEAD 92 |
| 30 mg | white rectangle tablet, 19 mm, scored to split in 3 | UPARROWHEAD 93 |
Bryant Ranch Prepack
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | white oval tablet, 10 mm, scored to split in 2 | UPARROWHEAD 91 |
Direct_rx
| Strength | Looks like | Imprint |
|---|---|---|
| 15 mg | white rectangle tablet, 16 mm, scored to split in 3 | U 246 |
Northwind Health Company, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 7.5 mg | white oval tablet, 9 mm, scored to split in 2 | UPARROWHEAD 90 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
4 recalls since 2020
- Apr 2026 · Unichem Pharmaceuticals USA Inc. · Class III
Subpotent drug - Oct 2023 · Ncs Healthcare of Kentucky Inc · Class III
Presence of Foreign Tablets: Potential of stray tablet(s) of Amlodipine Besylate 10 mg Tablet within the recalled lots - Feb 2023 · Accord Healthcare, Inc. · Class II
CGMP Deviations: recalling drug products following an FDA inspection. - May 2021 · Oxford Pharmaceuticals, LLC · Class II
Presence of Foreign Tablets/Capsules
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.